Euro Roundup: EFPIA proposal seek to reverse EU’s shrinking share of R&D pie (Cell and Gene Therapy Catapult - Regulatory Round-up – November 2022)
Fiche du document
25 janvier 2023
- handle: 10670/1.lrvw99
Sujets proches
Varnish paints Paints Enamel paints Products, Manufactured Manufactured goods Products Manufactured products Industrial production Industry Therapy, Gene Federation of Europe Pan Europa movement Paneuropean federation United States of Europe (Proposed) Council of Europe countries Controlled clinical trials Randomized clinical trials Trials, Clinical Patient trials of new treatments Carcinoma Cancers Malignancy (Cancer) Malignant tumors Relations with friends and associates Associates CompanionsCiter ce document
adelage, « Euro Roundup: EFPIA proposal seek to reverse EU’s shrinking share of R&D pie (Cell and Gene Therapy Catapult - Regulatory Round-up – November 2022) », ELSIBI, ID : 10670/1.lrvw99
Métriques
Partage / Export
Résumé
A new report published by Charles River Associates for the European Federation of Pharmaceutical Industries and Associations (EFPIA) paints a challenging picture of falling competitiveness in Europe, with the global share of pharmaceutical R&D investment, clinical trials and manufacturing output all decreasing. The situation is most acute for Advanced Therapies Medicinal Products (ATMPs) – tissue, gene and cell therapies – used to prevent, treat and cure rare conditions, including some cancer...